Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 1
Submit an article Journal homepage
251
Views
2
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of ticagrelor in acute coronary syndromes

Martin Henriksson Department of Health Economics, AstraZeneca Nordic, Astraallén, B674, 151 85 Södertälje, Sweden. [email protected]; Center for Medical Technology Assessment, Department of Medical & Health Sciences, Linköping University, Linköping 581 83, Sweden; Department of Health Economics, AstraZeneca Nordic, Astraallén, B674, 151 85 Södertälje, Sweden. [email protected]; Center for Medical Technology Assessment, Department of Medical & Health Sciences, Linköping University, Linköping 581 83, Sweden
&
Magnus Janzon Center for Medical Technology Assessment, Department of Medical & Health Sciences, Linköping University, Linköping 581 83, Sweden; Division of Cardiovascular Medicine, Department of Medicine & Health Sciences, Faculty of Health Sciences, Linköping University, Department of Cardiology UHL, County Council of Östergötland, Linköping University Hospital, 581 85 Linköping, Sweden; Center for Medical Technology Assessment, Department of Medical & Health Sciences, Linköping University, Linköping 581 83, Sweden; Division of Cardiovascular Medicine, Department of Medicine & Health Sciences, Faculty of Health Sciences, Linköping University, Department of Cardiology UHL, County Council of Östergötland, Linköping University Hospital, 581 85 Linköping, Sweden
Pages 9-18 | Published online: 09 Jan 2014

References

  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
  • Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).
  • Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad. Med. J. 80(941), 155–164 (2004).
  • Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J. 27(6), 647–654 (2006).
  • Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308(6921), 81–106 (1994).
  • Mehta SR, Yusuf S, Peters RJ et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
  • Steinhubl SR, Berger PB, Mann JT et al.; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
  • Weintraub WS, Mahoney EM, Lamy A et al.; CURE Study Investigators. Long-term cost–effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J. Am. Coll. Cardiol. 45(6), 838–845 (2005).
  • Mahoney EM, Mehta S, Yuan Y et al.; CURE Study Investigators. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am. Heart J. 151(1), 219–227 (2006).
  • Mahoney EM, Wang K, Arnold SV et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction TRITON-TIMI 38. Circulation 121(1), 71–79 (2010).
  • Kuliczkowski W, Witkowski A, Polonski L et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 30(4), 426–435 (2009).
  • van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31(2), 195–204 (2005).
  • Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27(9), 1038–1047 (2006).
  • Single dose pharmacokinetics and pharmacodynamics of AZD6140 – an oral reversible ADP receptor antagonist. Haematologica 89(Suppl. 7), 14–15 (2004).
  • Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577–2585 (2009).
  • Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121(10), 1188–1199 (2010).
  • James S, Akerblom A, Cannon CP et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157(4), 599–605 (2009).
  • Cannon CP, Harrington RA, James S et al.; PLATO investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375(9711), 283–293 (2010).
  • Steg PG, James S, Harrington RA et al.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122(21), 2131–2141 (2010).
  • James S, Angiolillo DJ, Cornel JH et al.; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 31(24), 3006–3016 (2010).
  • James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122(11), 1056–1067 (2010).
  • James SK, Roe MT, Cannon CP et al.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 342, d3527 (2011).
  • Mahaffey KW, Wojdyla DM, Carroll K et al.; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124(5), 544–554 (2011).
  • Storey RF, Becker RC, Harrington RA et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur. Heart J. 32(23), 2945–2953 (2011).
  • Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J. Am. Coll. Cardiol. 57(6), 672–684 (2011).
  • Wallentin L, James S, Storey RF et al.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320–1328 (2010).
  • Wijns W, Kolh P, Danchin N et al.; European Association for Percutaneous Cardiovascular Interventions. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio–Thoracic Surgery (EACTS). Eur. Heart J. 31(20), 2501–2555 (2010).
  • Authors/Task Force Members, Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33(20), 2569–2619 (2012).
  • Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58(24), 2550–2583 (2011).
  • Hillis LD, Smith PK, Anderson JL et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 58(24), 2584–2614 (2011).
  • Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
  • Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 15(7), 677–687 (2006).
  • Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials. Oxford University Press, Oxford, UK (2007).
  • Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford University Press, Oxford, UK (2006).
  • Sculpher MJ, Lozano-Ortega G, Sambrook J et al. Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost–effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am. Heart J. 157(5), 845–852 (2009).
  • Palmer S, Sculpher M, Philips Z et al. Management of non-ST-elevation acute coronary syndromes: how cost–effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int. J. Cardiol. 100(2), 229–240 (2005).
  • Henriksson M, Epstein DM, Palmer SJ et al. The cost–effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart 94(6), 717–723 (2008).
  • Briggs A, Mihaylova B, Sculpher M et al.; EUROPA Trial Investigators. Cost–effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 93(9), 1081–1086 (2007).
  • Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M, for the PLATO health economic substudy group. Cost–effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur. Heart J. 34(3), 220–228 (2012).
  • Mittmann N, Chan BC, Seung SJ, Liovas AM, Cohen EA. Cost–effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: results from the PLATO study: a Canadian analysis. Value Health 14(7), A378–A379 (2011).
  • Thurston S, Heeg B, Hofsté C. Ticagrelor for the treatment of acute coronary syndromes (ACS): a Dutch analysis based on the Plato Trial. Value Health 14(7) A380 (2011).
  • Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost–effectiveness analysis. Value Health 14(4), 483–491 (2011).
  • Janzon M, Lundborg E, Henriksson M et al. Health economics in the PLATelet inhibition and patient Outcomes (PLATO) randomised trial: report on within trial resource use patterns. Circulation 122(21 Suppl. 1), A17295 (2011).
  • Delgado-Ortega L, López-Sendón JL, Heras Fortuny M et al. Health economic evaluation of ticagrelor in patients with acute coronary patients (ACS) based on the Plato Study from a Spanish health care perspective. Value Health 14(7), A372 (2011).
  • Nikolic E, Henriksson M, Mellstrom C et al. Based on data from the PLATO study ticagrelor reduces non-drug health-care costs compared with clopidogrel in patients with acute coronary syndromes (ACS) from a Polish healthcare perspective. Presented at: 8th Annual HTAi Conference. Rio de Janeiro, Brazil, 27–29 June 2011.
  • Dolan P. Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997).
  • Garcia-Castillo A, De-los-Rios M, Polanco AC, Ramirez MA, Nikolic E, Mellström C. Long-term cost–effectiveness analysis of ticagrelor in patients with acute coronary syndrome (ACS) from a Mexican public and private health care perspective based on data from the PLATO Trial. Value Health 14(7), A379–A380 (2011).
  • Macioch T, Niewada M, Perkowski P, Mellström C, Budaj A. Long-term cost–effectiveness analysis of ticagrelor in patients with acute coronary syndrome from a Polish health care perspective. Value Health 14(7), A377 (2011).
  • Nicolau JC, Piha T, Nikolic E, Rikner K, Mellström C. Long term cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes from a Brazilian public healthcare perspective based on data from the PLATO Trial. Value Health 14(7), A380 (2011).
  • Janzon M. Treatment strategies in unstable coronary artery disease, economic and quality of life evaluations [dissertation]. Medical dissertation No. 811, Linköping University, Linköping, Sweden (2003).
  • Mahoney EM, Jurkovitz CT, Chu H et al.; TACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Cost and cost–effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288(15), 1851–1858 (2002).
  • Stenestrand U, Johansson S, Janzon M, Wallentin L. The platelet inhibition and patients outcomes trial is representative of patients with acute coronary syndromes in a national heart registry. Presented at: The 59th Annual Scientific Session of the American College of Cardiology (ACC). Atlanta, GA, USA, 14–16 March 2010.
  • Roe MT, Armstrong PW, Fox KA et al.; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367(14), 1297–1309 (2012).
  • Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 26(9), 753–767 (2008).
  • Ades AE, Sculpher M, Sutton A et al. Bayesian methods for evidence synthesis in cost–effectiveness analysis. Pharmacoeconomics 24(1), 1–19 (2006).
  • Sutton AJ. Methods for Meta-Analysis in Medical Research. Wiley, NY, USA (2000).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.